(Q46319341)

21 December 2017

title

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia (English)

1 reference

21 December 2017

1 reference

acute myeloid leukemia

1 reference

12

1 reference

21 December 2017

Manoj Raghavan

M Raghavan

6

0 references

Benjamin Davies

B Davies

17

0 references

Sylvie Freeman

S Freeman

4

0 references

Paresh Vyas

P Vyas

25

0 references

Charles Craddock

C Craddock

1

0 references

author name string

L Quek

2

1 reference

21 December 2017

N Goardon

3

1 reference

21 December 2017

S Siddique

5

1 reference

21 December 2017

A Aztberger

7

1 reference

21 December 2017

A Schuh

8

1 reference

21 December 2017

D Grimwade

9

1 reference

21 December 2017

A Ivey

10

1 reference

21 December 2017

P Virgo

11

1 reference

21 December 2017

T McSkeane

13

1 reference

21 December 2017

J Arrazi

14

1 reference

21 December 2017

S Knapper

15

1 reference

21 December 2017

C Brookes

16

1 reference

21 December 2017

A Price

18

1 reference

21 December 2017

K Wall

19

1 reference

21 December 2017

M Griffiths

20

1 reference

21 December 2017

J Cavenagh

21

1 reference

21 December 2017

R Majeti

22

1 reference

21 December 2017

I Weissman

23

1 reference

21 December 2017

A Burnett

24

1 reference

21 December 2017

publication date

6 November 2012

1 reference

21 December 2017

published in

Leukemia

1 reference

21 December 2017

volume

27

1 reference

21 December 2017

issue

5

1 reference

21 December 2017

page(s)

1028-1036

1 reference

21 December 2017

Therapeutic advances in acute myeloid leukemia

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

Stem cell gene expression programs influence clinical outcome in human leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

DNMT3A Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

7 January 2021

Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

7 January 2021

Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

7 January 2021

Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

7 January 2021

Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

7 January 2021

Regression Models and Life-Tables (with discussion)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.312

7 January 2021

Identifiers

DOI

10.1038/LEU.2012.312

1 reference

21 December 2017

1 reference

21 December 2017